Literature DB >> 7638569

Nonsteroidal anti-inflammatory drugs and upper gastrointestinal bleeding, identifying high-risk groups by excess risk estimates.

J Hallas1, J Lauritsen, H D Villadsen, L F Gram.   

Abstract

BACKGROUND: The relationship between use of nonsteroidal anti-inflammatory drugs (NSAID) and severe upper gastrointestinal bleeding (UGB) has been established beyond reasonable doubt. The literature on risk factors has almost exclusively focused on comparisons of relative risks in subgroups of patients: men versus women, old versus young and so forth. However, from a pragmatic, clinical viewpoint, only the excess risk provides a meaningful, robust measure of the magnitude of risk factors. The purpose of the study was to determine the excess risks in subgroups of patients and to characterize the utilization pattern of NSAIDs.
METHODS: A registry-based cohort study was conducted in a prescription and diagnosis registry in Odense, which covered a population of 207,000 persons for a period of 19 months.
RESULTS: In total, 183 (113 men and 70 women) UGB patients were identified, of whom 37 were current users of NSAIDs. The standardized incidence rate of UGB was 46 per 100,000 person-years for nonexposed and 253 per 100,000 person-years for exposed person-time, yielding an excess risk of 207 per 100,000 person-years (confidence interval (CI), 132-319) and a standardized incidence ratio (SIR) of 5.5 (CI, 3.9-7.9). Men had higher excess risk than women (277 versus 150 per 100,000 person-years). The SIR decreased with increasing duration of exposure. The excess risk was particularly high in persons aged 75 years or more (1258 per 100,000 person-years) and in patients with a history of peptic ulcer (879 per 100,000 person-years), being about 10- and 5-fold higher than in the complementary groups. NSAID utilization was remarkably sporadic. We found 31,503 users and a median purchase of 20 defined daily doses. Short-term use was highly prevalent in all age groups. Women, the elderly, and persons with a history of ulcer had a higher prevalence of NSAID use than others.
CONCLUSIONS: A history of peptic ulcer is associated with adverse outcome of NSAID therapy and should be regarded as a relative contraindication. A similarly strong effect of high age was shown. Male sex and short-term use are minor risk factors. The incidence of NSAID-related UGB can probably be reduced without affecting the overall utilization of NSAIDs.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7638569     DOI: 10.3109/00365529509093304

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  23 in total

1.  Factors involved in gastrointestinal bleeding in advanced cancer patients followed at home.

Authors:  Sebastiano Mercadante; Flavio Fusco; Alessandro Valle; Fabio Fulfaro; Alessandra Casuccio; Stefania Silvestro; Emanuela Donelli
Journal:  Support Care Cancer       Date:  2003-12-12       Impact factor: 3.603

2.  Treatment for Helicobacter pylori infection and risk of Parkinson's disease in Denmark.

Authors:  H H Nielsen; J Qiu; S Friis; L Wermuth; B Ritz
Journal:  Eur J Neurol       Date:  2012-01-17       Impact factor: 6.089

Review 3.  Gastroenterology services in the UK. The burden of disease, and the organisation and delivery of services for gastrointestinal and liver disorders: a review of the evidence.

Authors:  J G Williams; S E Roberts; M F Ali; W Y Cheung; D R Cohen; G Demery; A Edwards; M Greer; M D Hellier; H A Hutchings; B Ip; M F Longo; I T Russell; H A Snooks; J C Williams
Journal:  Gut       Date:  2007-02       Impact factor: 23.059

4.  Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies.

Authors:  L A García Rodríguez; S Hernández-Díaz; F J de Abajo
Journal:  Br J Clin Pharmacol       Date:  2001-11       Impact factor: 4.335

5.  An epidemiological approach to assess the economic burden of NSAID-induced gastrointestinal events in The Netherlands.

Authors:  R M Herings; O H Klungel
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

6.  Relative contribution of mucosal injury and Helicobacter pylori in the development of gastroduodenal lesions in patients taking non-steroidal anti-inflammatory drugs.

Authors:  C J Hawkey; J Naesdal; I Wilson; G Långström; A J Swannell; R A Peacock; N D Yeomans
Journal:  Gut       Date:  2002-09       Impact factor: 23.059

7.  Heavy users of non-steroidal anti-inflammatory drugs: a nationwide prescription database study in Finland.

Authors:  Arja Helin-Salmivaara; Timo Klaukka; Risto Huupponen
Journal:  Eur J Clin Pharmacol       Date:  2003-08-21       Impact factor: 2.953

8.  Bisphosphonate increases risk of gastroduodenal ulcer in rheumatoid arthritis patients on long-term nonsteroidal antiinflammatory drug therapy.

Authors:  Kazumasa Miyake; Masanori Kusunoki; Yoko Shinji; Tomotaka Shindo; Tetsuro Kawagoe; Seiji Futagami; Katya Gudis; Taku Tsukui; Atsushi Nakajima; Choitsu Sakamoto
Journal:  J Gastroenterol       Date:  2009-02-13       Impact factor: 7.527

9.  Antacid (A02A) and antiulcer (A02B) drug prescription patterns: predicting factors, dosage and treatment duration.

Authors:  M M Morales Suárez-Varela; M A Pérez-Benajas; V J Girbes Pelechano; A Llopis-González
Journal:  Eur J Epidemiol       Date:  1998-06       Impact factor: 8.082

Review 10.  A composite screening tool for medication reviews of outpatients: general issues with specific examples.

Authors:  Peter A G M De Smet; Wilma Denneboom; Cees Kramers; Richard Grol
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.